# Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage

Study · id `cardio:ct-nct07144956` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07144956](<https://clinicaltrials.gov/study/NCT07144956>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07144956

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 630 participants.

## Technical summary

Registry record NCT07144956. Randomized; triple masking; primary purpose treatment. Start 2025-12-15 (anticipated); primary completion 2029-12-14 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 630 participants (planned count; ClinicalTrials.gov record NCT07144956, source copy `cardio:ctgov-nct07144956-2025-09-10`, retrieved 2026-10-31)
- Planned start: 2025-12-15 (anticipated) (ClinicalTrials.gov record NCT07144956, source copy `cardio:ctgov-nct07144956-2025-09-10`, retrieved 2026-10-31)
- Primary completion: 2029-12-14 (anticipated) (ClinicalTrials.gov record NCT07144956, source copy `cardio:ctgov-nct07144956-2025-09-10`, retrieved 2026-10-31)
- Completion: 2029-12-14 (anticipated) (ClinicalTrials.gov record NCT07144956, source copy `cardio:ctgov-nct07144956-2025-09-10`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07144956-2025-09-10`, retrieved 2026-10-31)

## The registry's words

- Brief title: Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage
- Acronym: CASH
- Condition: Aneurysmal Subarachnoid Hemorrhage
- Intervention (Biological): Cilostazol (Pletal®) 100 mg Tablets
- Intervention (Drug): Placebo
- Intervention (Drug): Nimodipine group
- Lead sponsor: Centre Hospitalier St Anne
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Subarachnoid hemorrhage (`cardio:subarachnoid-hemorrhage`)
- Registry lists this organization as the lead sponsor: Centre Hospitalier St Anne (`cardio:org-centre-hospitalier-st-anne`)

## Provenance

Content hash: acee1a100e13be774aa08f4053a2b639240037ca2713238fe0249f93d254ec0b
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
